Tirzepatide is a dual-agonist targeting GLP-1 and GIP receptors, while retatrutide is a triple-agonist that also activates the glucagon receptor
#GIhomeschooling ACGs Functional GI & Motility Disorders School & ACG/MIGI Midwest Regional Postgraduate Course Detroit, MI August 14-16, 2026 ACGs Obesity & Metabolic Disorders School & ACG/VGS/MASGNA Regional Postgraduate Course Williamsburg, VA August 28-30, 2026 GI Societies Oppose Proposed Federal Rule That Would Reshape Biomedical Research ACG opposes the recent OMB proposal to have political appointees approve all NIH research grants ACG Proudly Endorses the Patients First Act ACG is grateful to the GOP and Democratic Doctors Caucuses for introducing this crucial Medicare physician reimbursement bill Member Alert: Proposed 2027 Medicare Rules Would Cut GI Payments ACG is alarmed by CMS proposal for new efficiency cuts and changes to practice expense methodology Clinical and Translational Gastroenterology Clinical and Translational Gastroenterology is a peer-reviewed, open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology
If you see adverts or listings to buy retatrutide online, they should be avoided because the product may not be genuine, sterile, correctly dosed or legally supplied
GLP-1 agonism: Delays gastric emptying, suppresses appetite centrally via hypothalamic signaling, and enhances glucose-dependent insulin secretion
In the past year, many telehealth and digital health companies, including Hims & Hers competitor Ro, have jumped into the market, offering prescriptions for GLP-1s as part of an existing weight loss or chronic condition management program or creating a new service line targeting obesity care
